Multitargeted Self-Replicating RNA for Off-The-Shelf Cancer Precision Immunotherapeutics
Time: 4:30 pm
day: Day Two
Details:
- Replicate Bioscience’s self-replicating RNA platform supports a unique and powerful approach to preventing and reversing the emergence of common acquired resistance mutations
- Using multigenic self-replicating RNA we have created precision immunotherapeutics that can be dosed in combination with SOC approved cancer agents, thus maintaining selective pressure on the tumour
- Mechanistically, the combination of the Replicate immunotherapy and the SOC creates a lose-lose situation wherein wild-type tumour clones are controlled by the SOC treatment and resistance mutant positive clones die by the precision immunotherapeutic. We term this synthetic immune lethality
